Most Recent Additions*
NATURAL HISTORY AND RISK FACTORS OF BEDSIDE PERCUTANEOUS ENDOSCOPIC GASTROSTOMY TUBES IN THE ICU
Michael Dix, Lucy Chau, Ryan Soheim, Nadia Obeid, Arielle H. Gupta, and Cletus Stanton
Radiation-induced senescence: therapeutic opportunities
Jae Ho Kim, Stephen L. Brown, and Marcia N. Gordon
927: DABBING LUNG INJURY MANAGED BY VV ECMO
Eric Snowden and Amanda Godfrey
438: SAFETY AND EFFICACY OF CEFEPIME INTRAVENOUS PUSH VERSUS PIGGYBACK IN GRAM-NEGATIVE BACTEREMIA
Mary Fronrath, Kristin M. Griebe, Carolyn R. Martz, Michael P. Veve, and Zachary R. Smith
COMPARING NERVE BLOCK PAIN PUMPS TO STANDARD OF CARE IN PATIENTS FOLLOWING CARDIOTHORACIC SURGERY
David W. Gutenschwager, Laura Hencken, Kristin M. Griebe, Victor Coba, Hassan Nemeh, and Long To
Benign yellow-dot maculopathy: case report and review of the literature.
Venkatkrish M. Kasetty, Tejas U. Desai, and Uday R. Desai
Microbiomes in Acne Vulgaris and Their Susceptibility to Antibiotics in Indonesia: A Systematic Review and Meta-Analysis
Lili Legiawati, Paulus Anthony Halim, Magna Fitriani, Hardya Gustada Hikmahrachim, and Henry W. Lim
Prone Versus Supine Ventilation and Mortality Outcome in Intubated COVID-19 Patients, a Revision Letter
Mohamed Fayed and Wissam Maroun
Henry Ford Hospital Clinic Tower Construction
Henry Ford Hospital
Goitre Operation
Roy D. McClure
Essential Activities of the Hospital Organization Behind the Medical Work
Henry Ford Hospital
Method of Selection of Students to the School of Nursing
Henry Ford Hospital
New Patient Division: Following a Prospective Patient Through the Admission Period
Henry Ford Hospital
Molecular characterization and clinical outcomes of pancreatic neuroendocrine tumors (pNENs) harboring PAK4-NAMPT alterations
Ibrahim Azar, Nishant Gandhi, Misako Nagasaka, Jun Gong, Bassel Nazha, Khalil Choucair, Moh'd M. Khushman, Heloisa P. Soares, Wafik S. El-Deiry, Philip A. Philip, Emil Lou, Alex P. Farrell, Jeffrey Swensen, Matthew J. Oberley, Jim Abraham, Chadi Nabhan, Sanjay Goel, Wolfgang M. Korn, and Anthony F. Shields
A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic adenocarcinoma
Mandana Kamgar, Husain Y. Khan, Amro Aboukameel, Sahar Bannoura, Brian Y. Chung, Aniko Szabo, Yiwei Li, Mohammed N. Al Hallak, Philip A. Philip, Ben George, Kathleen K. Christians, Douglas B. Evans, Susan Tsai, Beth Erickson, Sanjeev Luther, Asfar S. Azmi, and William A. Hall
NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US)
Christopher H. Lieu, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim H. Sahin, Dustin A. Deming, Philip A. Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Jonathan M. Loree, Norman Wolmark, Greg Yothers, Thomas J. George, and Arvind Dasari
EFFICACY AND SAFETY OF EPTACOG BETA (RECOMBINANT HUMAN FVIIA) ACCORDING TO AGE IN PERSONS WITH HAEMOPHILIA A/B WITH INHIBITORS UNDERGOING SURGICAL PROCEDURES
W. Miesbach, M. Escobar, L. Boggio, S. Bonanad, G. Castaman, Y. Darguard, A. Giermasz, C. Hermans, Philip Kuriakose, D. Quon, M. Reding, D. Q. Tran, J. Windyga, D. Bonzo, C. Macie, and J. Mahlangu
Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922
Michael J. Overman, Katherine A. Guthrie, Mohamed E. Salem, Katrina S. Pedersen, Aparna Kalyan, Sarah Colby, Marwan Fakih, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, Howard S. Hochster, and Philip A. Philip
A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613
Kanwal P. S Raghav, Katherine A. Guthrie, Scott Kopetz, Benjamin R. Tan, Crystal S. Denlinger, Marwan Fakih, Michael J. Overman, Arvind Dasari, Larry R. Corum, Lee G. Hicks, Mital Patel, Benjamin T. Esparaz, Syed Mohammad A. Kazmi, Nitya Alluri, Sarah Colby, Sepideh Gholami, Philip J. Gold, E. Gabriela Chiorean, Howard S. Hochster, and Philip A. Philip
APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation-ECOG-ACRIN EA2192
Kim A. Reiss, Sung C. Hong, Anup Kasi, Eileen M. O'Reilly, Shishir K. Maithel, Xin Yao, Stanley R. Hamilton, Ben Boursi, Michael J. Pishvaian, Samuel J. Klempner, Susan M. Domchek, Paul J. Catalano, E. Gabriel Chiorean, Philip A. Philip, and Peter J. O'Dwyer
*Updated as of 03/22/23.
